Τόμος 32 (2018) – Τεύχος 3 –Άρθρο 1 – Review of Clinical Pharmacology and Pharmacokinetics – Διεθνής Έκδοση – Volume 32 (2018) – Issue 3 – Article 1 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

By | | Πλήρες Κείμενο στα Αγγλικά - Full Text in English
Τίτλος – Title

Prevalence of cardiovascular disorders in Greek women with Polycystic Ovary Syndrome. A retrospective study
Συγγραφέας – Author

Giannoula Kyrkou1, Eftichios Trakakis2, Achilleas Attilakos1, Kleanthi Gourounti 3, Aikaterini Lykeridou3

1Third Department of Pediatric, University of Athens “Attikon” Hospital, Athens, Greece

2Third Department of Obstetrics & Gynecological, University of Athens “Attikon” Hospital, Athens, Greece

3Midwifery Department, University of West Attica, Athens, Greece
Παραπομπή – Citation

G. Kyrkou. E. Trakakis, A. Attilakos, K. Gourounti, A. Lykeridou. Prevalence of cardiovascular disorders in Greek women with Polycystic Ovary Syndrome. A retrospective study. Review Clin. Pharmacol. Pharmacokinet. 2018, 32, 3, 109-113
Ημερομηνία Δημοσιευσης – Publication Date
16-07-2018
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά – English
Λέξεις κλειδιά – Keywords
Polycystic Ovary Syndrome, prevalence, cardiovascular disorders
Λοιποί Όροι – Other Terms

Μελέτη Ανασκόπησης

Retrospective study
Περίληψη –Summary

Polycystic ovary syndrome (PCOS) has been correlated with cardiovascular disorders like arterial hypertension, hyperlipidemia, as well as glucose metabolic disorders.

Aim: Aim of this study was to investigate the prevalence of cardiovascular disorders in Greek women with PCOS.

Method and material: 230 Greek women, who have been diagnosed with PCOS according to the criteria of the Rotterdam ESHRE, aged from 12 to 44 years, have been included in the study. The triglycerides level, the systolic and the diastolic pressure levels have been analyzed.

Results: The prevalence of the Greek women with PCOS is 10% International Diabetes Federation  (IDF). The high-density lipoprotein (HDL) plasma levels were in 26,5% lower than <50mg/dl.

Furthermore the triglycerides (TG) plasma levels were in 10,4% higher than >150mg/dl. Finally the diastolic blood pressure was in 6,1% higher than >85mm/Hg and the systolic blood pressure was in 4,3% higher than >130mm/Hg. The pathological variables

of the cardiovascular disorders in all age groups have the primary findings of the decreased levels of HDL, secondary findings the increases levels of TG and finally the gradual increased observed in diastolic blood pressure.

In conclusion: Women with PCOS have an increased risk of cardiovascular disorders and incidence of diabetes type 2, so the systematic information and the follow up will prevent future pathological situations.
Αναφορές- References
  1. Azziz R., Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and the features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:245-249
  2. Asuncion M., Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
  3. Hart R., Hickey M, Franks S (2004) Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18:671-683
  4. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 No 1:41-47
  5. Teede, H.J., Hutchison, S., Zoungas, S., Meyer, C., 2006. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 30, 45–53.
  6. Westerveld, H.E., Hoogendoorn, M., de Jong, A.W., Goverde, A.J., Fauser, B.C., Dallinga-Thie, G.M., 2008. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacology and Therapeutics 119, 223–241.
  7. Malik S, Wong ND. Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis. Expert Rev Cardiovasc Ther. 2009;7(3):273–80. doi: 10.1586/14779072.7.3.273.
  8. Third Report of the National Cholesterol Education Program (NCEP) 2002 Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
  9. The IDF consensus worldwide definition of the metabolic syndrome.

http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf, last accessed in August 2007

  1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation.112:2735-52.
  2. The IDF consensus worldwide definition of the metabolic syndrome in children and adolescents http://www.idf.org/webdata/docs/Mets_definition_children.pdf accessed in 2007
  3. Ferriman D, Gallwey JD (1961) Clinical assessment of body hairgrowth in women. J Clin Endocrinol Metab 21:1440–1447
  4. Kauffman, R.P., Baker, T.E., Baker, V.M., DiMarino, P., Castracane, V.D., 2008. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. American Journal of Obstetrics and Gynecology. 198, 670.e1–670.e10
  5. Cussons AJ, Stuckey BG, Watts GF. Metabolic syndrome and cardiometabolic risk in PCOS. Curr. Diab. Rep. Feb 2007;7(1):66-73
  6. Isomaa B, Almgren P, Tuomi T, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689
  7. Suzuki T, Homma S,. treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome. Med Clin North Am. Nov 2007;91(6):1211-23,x
  8. Cheung LP, Ma RC, Lam PM, et al. (2008) Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 23:1431-143
  9. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA (2006) Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS Eur J Endocrinol 154:141-145
  10. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in with polycystic ovary syndrome. CLin Endocrinol Metab 2005; 90:1929-1935
  11. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA (2003) Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 18:2289-2293
  12. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S (2003) Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 61:29-37
  13. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. (2005) MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 7:397-405
  14. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. (2004) Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 147:106-112
  15. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG (2008) Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 23:2352-2358
  16. Bhattacharya SM (2008) Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. J Obstet Gynaecol Res 34:62-66
  17. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106:131-137
  18. Marcondes JA, Hayashida SA, Barcellos CR, Rocha MP, Maciel GA, Baracat EC (2007) Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metabol 51:972-979
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6583

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Τι είναι η Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Review of Clinical Pharmacology and Pharmacokinetics-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση
Articles Published in Review of Clinical Pharmacology and Pharmacokinetics-International Edition

Συντακτικη Επιτροπή-Editorial Board

Bookmark the permalink.

Comments are closed.